SCHEMBL4059829

SCHEMBL4059829

c1ccc(-c2cnc3nc(-c4ccc5c(c4)OCO5)[nH]c3c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.52
TNKS O95271 1/20 0.52
TNKS2 Q9H2K2 1/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HPGD P15428 3/20 0.52
MAPT P10636 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
LMNA P02545 1/20 0.52
HTT P42858 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
POLB P06746 1/20 0.47
PKM P14618 2/20 0.46
ADORA2A P29274 2/20 0.45
ADORA1 P30542 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4053030 0.93 AURKA (0.45) PARP1TNKSTNKS2MEN1KMT2A
SCHEMBL4062970 0.86 TGFBR1 (0.54) PARP1TNKSTNKS2MEN1KMT2A
SCHEMBL4055850 0.85 SCD (0.53) PARP1TNKSTNKS2MEN1KMT2A
SCHEMBL4051595 0.85 AURKA (0.57) PARP1MEN1KMT2AKDM4EALDH1A1
SCHEMBL4058862 0.85 CLK1 (0.46) PARP1TNKSTNKS2MEN1KMT2A
SCHEMBL4055474 0.84 PTGS2 (0.50) PARP1TNKSTNKS2MEN1KMT2A
SCHEMBL4059563 0.84 PARP1 (0.49) PARP1TNKSTNKS2MEN1KMT2A
SCHEMBL4063472 0.84 KDM4E (0.48) PARP1TNKSTNKS2MEN1KMT2A
SCHEMBL4060379 0.82 AURKA (0.56) PARP1TNKSTNKS2MEN1KMT2A
SCHEMBL4059856 0.82 MAPT (0.46) PARP1MEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B PARP1 1089/4885TNKS 1134/4885TNKS2 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.